ArticlePloS one2026
Long noncoding RNA Gpr137b-ps mediates 15-PGDH-induced angiogenesis in brain microvasculature following tMCAO in mice.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAngiogenesis is essential for recovery following ischemic stroke, as brain microvascular endothelial cells (BMVECs) drive vascular repair. 15-hydroxyprostaglandin dehydrogenase (15-PGDH) is a major regulator of endothelial function in some vascular contexts, but it is unknown whether 15-PGDH plays a significant role in angiogenesis following stroke. Notably, based on preliminary bioinformatics prediction of their 3'UTR interaction, we hypothesize that Gpr137b-ps-a pseudogene-derived lncRNA originating from Gpr137b-forms a regulatory link with 15-PGDH to modulate this process (i.e., post-stroke angiogenesis) by regulating 15-PGDH expression, though its specific functional mechanism in this context remains largely unknown.
methodsTo address this gap, we used mouse middle cerebral artery occlusion (MCAO) model in vivo and BMVEC oxygen-glucose deprivation/reoxygenation (OGD/R) model in vitro. We modulated 15-PGDH via siRNA and Gpr137b-ps via mimics, and assessed angiogenesis using migration, tube formation, and cell-cycle assays, with expression and localization of key molecules verified by standard molecular techniques.
resultsBoth MCAO and OGD/R successfully induced ischemia, with significant upregulation of 15-PGDH and Gpr137b-ps in ischemic tissues and BMVECs (P < 0.05). Despite this concurrent upregulation, 15-PGDH promoted angiogenesis (silencing reduced BMVEC proliferation, migration, and tube formation; P < 0.01), whereas Gpr137b-ps overexpression suppressed 15-PGDH protein levels and inhibited angiogenesis-effects that were rescued by re-expressing 15-PGDH.
conclusionTogether, our findings identify Gpr137b-ps/15-PGDH as a key feedback regulatory axis: while both Gpr137b-ps and 15-PGDH are upregulated under ischemia, Gpr137b-ps (a negative regulator of angiogenesis) suppresses 15-PGDH (a pro-angiogenic factor) to repress excessive post-stroke angiogenesis via inhibiting BMVEC proliferation, migration, and cell-cycle progression. The data support an association and partial dependency between this axis and angiogenic processes, highlighting it as a potential therapeutic target (e.g., via inhibiting Gpr137b-ps) for vascular repair after ischemic stroke.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.